Literature DB >> 15546075

The influence of human N-acetyltransferase genotype on the early bactericidal activity of isoniazid.

P R Donald1, F A Sirgel, A Venter, D P Parkin, H I Seifart, B W van de Wal, C Werely, P D van Helden, J S Maritz.   

Abstract

The elimination of isoniazid is subject to the influence of the N-acetyltransferase 2 (NAT2) genotype, and individuals may be homozygotic slow, heterozygotic fast, or homozygotic fast acetylators of isoniazid. The early bactericidal activity (EBA) of an antituberculosis agent can be determined by quantitative culture of Mycobacterium tuberculosis in sputum samples obtained from patients with pulmonary tuberculosis during the first days of treatment. In these studies, the EBA of isoniazid during the first 2 days of treatment was determined for 97 patients with sputum smear-positive pulmonary tuberculosis following isoniazid doses of < or =37.5 mg, 75 mg, 150 mg, 300 mg, and 600 mg. The NAT2 genotype was determined in 70 patients, and the association between EBA and genotype was examined in this subgroup. Similarly, the relationship between EBA and isoniazid serum concentration was evaluated in 87 patients. The mean EBA of isoniazid increased with dose, but it levelled off between doses of 150 mg (mean EBA, 0.572) and 300 mg (mean EBA, 0.553). Significant differences were found in the mean EBA of isoniazid between the homozygous slow acetylator group and the heterozygous fast acetylator group and between the homozygous slow acetylator group and the homozygous fast acetylator group, but not between the heterozygous fast acetylator group and the homozygous fast acetylator group. The EBA appeared to reach a maximum at a 2-h isoniazid concentration of 2-3 microg/mL. These data confirm a significant effect of NAT2 genotype on the EBA of isoniazid over a range of doses.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15546075     DOI: 10.1086/424999

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  30 in total

Review 1.  An oracle: antituberculosis pharmacokinetics-pharmacodynamics, clinical correlation, and clinical trial simulations to predict the future.

Authors:  Jotam Pasipanodya; Tawanda Gumbo
Journal:  Antimicrob Agents Chemother       Date:  2010-10-11       Impact factor: 5.191

2.  Population modeling and simulation study of the pharmacokinetics and antituberculosis pharmacodynamics of isoniazid in lungs.

Authors:  L Lalande; L Bourguignon; S Bihari; P Maire; M Neely; R Jelliffe; S Goutelle
Journal:  Antimicrob Agents Chemother       Date:  2015-06-15       Impact factor: 5.191

3.  Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.

Authors:  Jan-Willem C Alffenaar; Simon Tiberi; Roger K Verbeeck; Scott K Heysell; Martin P Grobusch
Journal:  Clin Infect Dis       Date:  2016-10-06       Impact factor: 9.079

4.  Effect of efavirenz-based antiretroviral therapy and high-dose rifampicin on the pharmacokinetics of isoniazid and acetyl-isoniazid.

Authors:  Maxwell T Chirehwa; Helen McIlleron; Lubbe Wiesner; Dissou Affolabi; Oumou Bah-Sow; Corinne Merle; Paolo Denti
Journal:  J Antimicrob Chemother       Date:  2019-01-01       Impact factor: 5.790

Review 5.  Pharmacologic considerations in use and development of antituberculosis drugs.

Authors:  Geraint Davies
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-18       Impact factor: 6.915

6.  Role of the N-acetylation polymorphism in solithromycin metabolism.

Authors:  David W Hein; Mark A Doll
Journal:  Pharmacogenomics       Date:  2017-04-24       Impact factor: 2.533

7.  Time Trends in Sputum Mycobacterial Load and Two-Day Bactericidal Activity of Isoniazid-Containing Antituberculosis Therapies.

Authors:  Veronique De Jager; Lize van der Merwe; Amour Venter; Peter R Donald; Andreas H Diacon
Journal:  Antimicrob Agents Chemother       Date:  2017-03-24       Impact factor: 5.191

8.  Isoniazid bactericidal activity and resistance emergence: integrating pharmacodynamics and pharmacogenomics to predict efficacy in different ethnic populations.

Authors:  Tawanda Gumbo; Arnold Louie; Weiguo Liu; David Brown; Paul G Ambrose; Sujata M Bhavnani; George L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2007-04-16       Impact factor: 5.191

9.  Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2.

Authors:  Ryuji Kubota; Masako Ohno; Tomoko Hasunuma; Hajime Iijima; Junichi Azuma
Journal:  Eur J Clin Pharmacol       Date:  2007-07-31       Impact factor: 2.953

10.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.